...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Bone >Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
【24h】

Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.

机译：在患有继发性骨质疏松症的儿童中治疗2年后，唑来膦酸可改善骨骼矿物质密度，减少骨骼更新并改善骨骼结构。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There are limited data on the use of bisphosphonate therapy for secondary osteoporoses in childhood, and no previous reports of the use of zoledronic acid in this group. We report 20 children with a variety of underlying primary diagnoses with associated secondary osteoporosis, who were treated with 3 monthly zoledronic acid for 2 years (annualised dose 0.1mg/kg/year). There was a significant improvement in lumbar spine (by 1.88 SD+/-1.24 over first 12 months, p<0.001) and total bone mineral density as assessed by dual energy absorptiometry (DXA) scans, with a similar increase in bone mineral content for lean tissue mass (mean increase 1.34 SD in first 12 months, p<0.001). Bone turnover was reduced with a suppression of both osteocalcin and alkaline phosphatase in the first 12 months of treatment. Skeletal architecture was improved, with increased second metacarpal cortical thickness from 2.44mm to 2.72mm (p<0.001) and improved vertebral morphometry, with 7 patients who had vertebral wedging at baseline showing improved anterior (p=0.017) and middle (p=0.001) vertebral height ratios. Aside from well reported transient side effects with the first dose, there were no adverse effects reported. No adverse effects on anthropometric parameters were seen over the course of the study. Despite all patients having sustained fragility fractures prior to treatment, no fractures were reported during the study period. Further evidence is required to confirm efficacy, with long term follow up required to assess the impact of treatment on fracture risk.
机译：关于在儿童期使用二膦酸盐治疗继发性骨质疏松症的数据有限，并且该组中没有以前使用唑来膦酸的报道。我们报告了20名具有各种潜在的主要诊断为继发性继发性骨质疏松症的儿童，这些儿童接受3个月的唑来膦酸治疗2年（年剂量0.1mg / kg /年）。通过双能量吸收仪（DXA）扫描评估，腰椎（前12个月降低1.88 SD +/- 1.24，p <0.001）和总骨矿物质密度显着改善，瘦骨矿物质含量也有类似的提高组织肿块（前12个月平均增加1.34 SD，p <0.001）。在治疗的前12个月，骨钙素和碱性磷酸酶的抑制可减少骨转换。骨骼结构得到改善，第二掌骨皮质厚度从2.44mm增加到2.72mm（p <0.001），并且椎体形态得到改善，基线时椎体楔入的7例患者前侧（p = 0.017）和中侧（p = 0.001）有所改善）椎高比。除了已报道的第一剂短暂的副作用外，没有副作用的报道。在研究过程中未见对人体测量学参数的不利影响。尽管所有患者在治疗前均患有持续的脆性骨折，但在研究期间没有骨折的报道。需要进一步的证据来确认疗效，并需要长期随访以评估治疗对骨折风险的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号